Press Release | Sat Apr 6, 2013 10:30am EDT

KYTHERA Biopharmaceuticals, Inc. Announces Positive Interim Results from Open-Label Phase IIIb Study of ATX-101 at the 11th Anti-Aging Medicine World Congress (AMWC)

* Reuters is not responsible for the content in this press release.